The immuno-oncology drug developer has filed for an $86.5m offering, having raised more than $115m in equity funding from investors including Taiho and Eli Lilly.
US-based immunotherapy developer Harpoon Therapeutics has filed to raise up to $86.3m in an initial public offering that would enable pharmaceutical companies Eli Lilly and Taiho to exit.
Harpoon is working on T cell engagers intended to treat diseases such as cancer by leveraging the body’s immune system, and aims to have advanced four drug candidates into clinical testing by the end of 2020.
The IPO proceeds will support clinical work on HPN424, a candidate that is in a…
